Clarity Pharmaceuticals (ASX:CU6) - Executive Chairman, Dr Alan Taylor
Executive Chairman, Dr Alan Taylor
Source: Clarity Pharmaceuticals
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Clarity Pharmaceuticals (CU6) doses its first patient in its therapeutic prostate cancer trial
  • The trial is a single-arm dose-escalation study, which will involve up to 44 patients in the US to determine the safety and efficacy of Clarity’s SAR-bisPSMA treatment
  • Following a review of the first patient’s data, the Safety Review Committee recommended the trial progress into therapeutic applications
  • Clarity says its results to date support the investigation of the optimised SAR-bisPSMA product in additional oncology indications
  • Clarity Pharmaceuticals is up 1.63 per cent and trading at 62.5 cents at 2:49 pm AEDT

Clarity Pharmaceuticals (CU6) has dosed its first patient in its therapeutic prostate cancer trial.

The study is a therapeutic phase of Clarity’s SAR-bisPSMA theranostic clinical trial, dubbed SECuRE, which is investigating targeted copper theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer.

The trial is a single-arm dose-escalation study, which will involve up to 44 patients in the US.

The aim of the trial is to determine the safety and efficacy of 67Cu-SAR-bisPSMA as a therapy.

Following a review of the first patient’s data, the trial’s Safety Review Committee recommended the trial progress into therapeutic applications.

Clarity said its preclinical and clinical results to date supported its investigation of the optimised SAR-bisPSMA product in additional oncology indications, particularly where the theranostic approach may have utility.

Clarity Executive Chairman Alan Taylor said the company is excited to progress our second theranostic trial and continue exploring the benefits of TCTs.

“Prostate cancer is one of the largest oncology indications and there is a significant unmet need for improved diagnosis and therapy of patients with this insidious disease,” Dr Taylor said.

“Moreover, the preliminary data suggests the optimised PSMA product could deliver clinical benefits in oncology indications beyond prostate cancer, which we are excited to explore in the near future.”

Clarity Pharmaceuticals was up 1.63 per cent and trading at 62.5 cents at 2:49 pm AEDT.

CU6 by the numbers
More From The Market Online
The Market Online Video

Market Close: Autumn’s ASX200 record breaking start

The ASX200 has closed the first day of Autumn at a new record 7745.6 points -…
The Market Online Video

Ark Mines (ASX:AHK) improves REE grades at Sandy Mitchell

North Queensland-based REE explorer Ark Mines (ASX:AHK) has proven higher-grade mineralisation is present on-site.

Week 9 Wrap-up: ASX hits 2 new ATHs on US inflation + the headlines that mattered

What a week. As US markets continue to go crazy after the American earnings season (read: NVIDIA), the ASX has done the same. 
OBM

Ora Banda Mining secures $30 M placement, marks progress toward second underground mine

Ora Banda Mining (ASX:OBM) has completed a single tranche placement, securing commitments at an issue price…